Tagged with access

Korea Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea.   At the moment the main concern is that Korean prices are too low Could you provide our readers with an introduction to…

France Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience.   We are the only specialty pharma player exclusively dedicated to neuroscience and it is important that this shines through in our dealings…

Spain Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches on the importance of the market access team in the fragmented Spanish healthcare ecosystem and his ambitions for Allergan throughout…

Malaysia Ewe Kheng Huat, executive director of PhAMA, the Malaysian association for innovative companies, describes the current market environment for innovative medicines in Malaysia, from the difficulties to enter the Malaysian market to the great opportunities the country can offer in terms of clinical research and shared services.   We believe…

Malaysia Lance Duan, general manager of Roche Malaysia, discusses the dynamic changes in the country’s health system and the possibilities that exist for Roche to establish a collaborative relationship with the new government. Duan also describes the many initiatives Roche has to support Malaysian patients from a varying degree of angles,…

Algeria Loic Galmard discusses the opportunities and challenges of setting up local production in Algeria, and the best strategies to increase market access and create a dialogue with the regulatory authorities. What are your first impressions of the local market in the 10 months that you have been here so far?…

Turkey Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to life-changing innovation. He also pinpoints MSD’s exceptional and enduring commitment to Turkey, which has led the company to emerge as…

UK With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new chemical entity launches, after USA and Germany, despite the uncertainty created by Brexit. Furthermore, she highlights the fact that the…

Turkey Elif Aral, country manager of Pfizer Turkey, stresses that Turkey will continue to be perceived as essential and important, where healthcare is a top priority with its young but aging population. In addition, as the newly appointed Chairman of the Board of Directors of the Association of Research-Based Pharmaceutical Companies…

Turkey Mark Dekker, general manager of Astellas in Turkey, describes the ever-increasing commitment of the company to Turkey and the recent doubling of Astellas’ portfolio in the country, while pinpointing the next steps ahead to further improve access to innovation in Turkey and ensure the country continues to be seen as…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…

UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients.   We do see a will and an intent from stakeholders, from government…